Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...

SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

Opening a business credit card is often framed as a way to separate expenses and earn basic rewards, but the real value can ...

FLOOD CONTROL composite image from INQUIRER FILE MANILA, Philippines — The floods came first. In Bulacan, Pampanga, and parts ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...

Since 2021, the U.S. Army and the Brazilian Army have conducted combined military exercises as part of Exercise Southern ...

We chose H&R Block as our best overall online tax service because of its transparent pricing, easy-to-use platform, and ...

Kamar Samuels, a Jamaican born educator with nearly two decades in the public school system, to be tapped as the next NYC ...

The companies that survive will look less like pyramids and more like swarms: small, autonomous AI-first pods that move and ...

SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

MIT researchers have developed a new method for designing 3D structures that can be transformed from a flat configuration ...

A new single-string method lets flat designs deploy into complex 3D structures, with potential uses in modular space habitats ...